Perceived Barriers to NGS-Based Molecular Profiling Among US Metastatic Breast Cancer Patients.

ABSTRACT: Background/Objectives: Next-generation sequencing (NGS)-based molecular profiling has revolutionized personalized medicine and unlocked new treatment options for cancer patients. Clinical guideline bodies agree that patients diagnosed with HR+/HER2- metastatic breast cancer (mBC) may benefit from comprehensive somatic genomic profiling to identify candidates for established targeted therapies and clinical trials, yet many patients are not receiving it due to a lack of widespread access to NGS. Methods: To better understand the perceived barriers (if any) to NGS tests in mBC, a study was conducted across multiple stakeholders including medical oncologists, nurses, physician assistants, lab directors, pathologists, payers, and patients. Results: This study revealed that

SUBMITTER: Cadirov N 

PROVIDER: S-EPMC12564138 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature